3 Growth Companies On Euronext Paris With 46% Revenue Growth

As the European markets face heightened caution due to escalating Middle East tensions, France's CAC 40 Index has seen a notable decline of 3.21%, reflecting broader investor wariness. Amidst these challenges, growth companies with high insider ownership on Euronext Paris stand out as potentially resilient options, often benefiting from aligned interests between management and shareholders during uncertain times.

Top 10 Growth Companies With High Insider Ownership In France

Name	Insider Ownership	Earnings Growth
Groupe OKwind Société anonyme (ENXTPA:ALOKW)	20.6%	36%
VusionGroup (ENXTPA:VU)	13.4%	81.7%
Icape Holding (ENXTPA:ALICA)	30.2%	33.9%
Arcure (ENXTPA:ALCUR)	21.4%	26.6%
La Française de l'Energie (ENXTPA:FDE)	19.9%	31.9%
S.M.A.I.O (ENXTPA:ALSMA)	17.4%	35.2%
STIF Société anonyme (ENXTPA:ALSTI)	16.4%	28.5%
Adocia (ENXTPA:ADOC)	11.9%	64%
Munic (ENXTPA:ALMUN)	27.1%	174.1%
MedinCell (ENXTPA:MEDCL)	15.8%	93.9%

Click here to see the full list of 21 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Exclusive Networks (ENXTPA:EXN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exclusive Networks SA is a global cybersecurity specialist focused on digital infrastructure, with a market cap of €2.13 billion.

Operations: The company's revenue is segmented into three primary regions: APAC with €480 million, EMEA contributing €4.19 billion, and the Americas generating €705 million.

Insider Ownership: 13.1%

Revenue Growth Forecast: 12.2% p.a.

Exclusive Networks is undergoing a significant transition as Clayton, Dubilier & Rice and Permira plan to take it private in a deal valued at €2.2 billion. The company, with 66.7% insider ownership by Permira and founder Olivier Breittmayer, has welcomed this move. Despite recent declines in profit margins from 5.5% to 2.7%, the firm's earnings are forecasted to grow significantly at 33.5% annually, outpacing the French market's growth rate of 12.2%.

• Get an in-depth perspective on Exclusive Networks' performance by reading our analyst estimates report here.
• Our valuation report here indicates Exclusive Networks may be overvalued.

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific with a market cap of €1.09 billion.

Operations: The company's revenue segments are comprised of €172.65 million from the Americas and €118.54 million from the Asia-Pacific region.

Insider Ownership: 19.6%

Revenue Growth Forecast: 10.4% p.a.

Lectra's insider ownership supports its growth trajectory, despite recent exclusion from the S&P Global BMI Index. The company's earnings are expected to grow significantly at 29.3% annually, outperforming the French market's forecasted growth rate of 12.2%. Although revenue is projected to increase by 10.4% per year, it remains below a high-growth threshold of 20%. Lectra trades at a substantial discount to its estimated fair value, with analysts anticipating a potential price increase of 20.1%.

• Delve into the full analysis future growth report here for a deeper understanding of Lectra.
• Our valuation report here indicates Lectra may be undervalued.

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a pharmaceutical company based in France that develops long-acting injectables across various therapeutic areas, with a market cap of €443.88 million.

Operations: The company generates its revenue from the pharmaceuticals segment, amounting to €11.95 million.

Insider Ownership: 15.8%

Revenue Growth Forecast: 46.2% p.a.

MedinCell's strong insider ownership aligns with its robust growth prospects, as it is forecast to achieve 46.2% annual revenue growth, outpacing the French market. The company is expected to become profitable within three years and trades significantly below estimated fair value. Recent strategic alliances, including a $1.9 billion collaboration with AbbVie and successful commercialization of UZEDY in partnership with Teva, bolster its innovative pipeline and financial outlook amidst recent governance changes.

• Click to explore a detailed breakdown of our findings in MedinCell's earnings growth report.
• Our comprehensive valuation report raises the possibility that MedinCell is priced lower than what may be justified by its financials.

Where To Now?

• Reveal the 21 hidden gems among our Fast Growing Euronext Paris Companies With High Insider Ownership screener with a single click here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com